eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR – Get Rating) CFO Michael Byrnes purchased 25,000 shares of the firm’s stock in a transaction on Tuesday, June 7th. The shares were acquired at an average cost of $1.33 per share, with a total value of $33,250.00. Following the completion of the acquisition, the chief financial officer now directly owns 29,233 shares in the company, valued at $38,879.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of eFFECTOR Therapeutics stock traded down $0.09 during trading hours on Tuesday, hitting $1.30. 155,100 shares of the company’s stock traded hands, compared to its average volume of 35,642. The stock has a 50 day simple moving average of $2.84 and a 200-day simple moving average of $4.93. The company has a quick ratio of 18.38, a current ratio of 18.38 and a debt-to-equity ratio of 0.75. eFFECTOR Therapeutics, Inc. has a twelve month low of $1.21 and a twelve month high of $40.42.
eFFECTOR Therapeutics (NASDAQ:EFTR – Get Rating) last announced its earnings results on Wednesday, March 16th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.69. The business had revenue of $0.31 million for the quarter. As a group, equities analysts forecast that eFFECTOR Therapeutics, Inc. will post -0.52 EPS for the current fiscal year.
Several research firms have recently weighed in on EFTR. Zacks Investment Research raised eFFECTOR Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a report on Friday. JMP Securities reiterated a “buy” rating and set a $8.00 target price on shares of eFFECTOR Therapeutics in a research report on Monday. Finally, Credit Suisse Group lowered their price target on eFFECTOR Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Thursday, March 17th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $16.74.
About eFFECTOR Therapeutics (Get Rating)
eFFECTOR Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on eFFECTOR Therapeutics (EFTR)
- It’s Time To PLAY With Dave & Buster’s
- Seagate Technology: Improved Fundamentals & Recovering Technicals
- It’s A Sweet Time To Buy The J.M. Smucker Co.
- Don’t Rush Out To Buy G-III Apparel
- Target’s Warning Is Dire News For The S&P 500
Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.